1 / 1
Dacomitinib(Vizimpro)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Pfizer Inc.
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Dacomitinib(Vizimpro) Instructions:Uses,Dosage, Side Effects
VIZIMPRO (dacomitinib) is an oral kinase inhibitor approved for the treatment of metastatic non-small cell lung cancer with specific EGFR mutations.
VIZIMPRO is a prescription medication classified as a kinase inhibitor, used primarily in the first-line treatment of metastatic non-small cell lung cancer (NSCLC). It targets tumors with EGFR exon 19 deletions or exon 21 L858R mutations, as identified by an FDA-approved test. The drug comes in tablet form and was initially approved in the U.S. in 2018.
